1.
Hale G: Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1995;1:175-187.
2.
Mone AP, Cheney C, Banks AL, Trindanapanis S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC: Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukaemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-279.
3.
Gribben JG, Hallek M: Rediscovering alemtuzumab: current and emerging theraputic role. Br J Haematol 2009;144:818-831.
4.
Stilgenbauer S, Zenz T: Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:481-488.
5.
D'Arena G, Guariglia R, La Rocca F, Trino S, Condelli V, De Martino L, De Feo V, Musto P: Autoimmune cytopenias in chronic lymphocytic leukemia. Clin Dev Immunol 2013;2013:730131.
6.
Laurenti L, Garzia M, Sabatelli M, Piccioni P, Sorà F, Leone G: Guillain-Barré syndrome following Varicella zoster reactivation in chronic lymphocytic leukemia treated with fludarabine. Haematologica 2002;87:ECR33.
7.
D'Arena G, Vigliotti ML, Pizza V, Tartarone A, Volpe G, Iodice G, Di Renzo N: Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2004;45:1489-1490.
8.
Tzachanis D, Hamdan A, Uhlmann EJ, Joyce RM: Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia. Acta Haematol 2014;132:240-243.
9.
Klotz L, Wiendl H: Monoclonal antibodies in neuroinflammatory diseases. Expert Opin Biol Ther 2013;13:831-846.
10.
Laurenti L, Vannata B, Innocenti I, Autore F, Santini F, Sica S, Efremov D: The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 2013;5:e2013027.
11.
Riches JC, Ramsay AG, Gribben JG: T-cell function in chronic lymphocytic leukemia. Semin Cancer Biol 2010;20:431-438.
12.
Costelloe L, Jones J, Coles A: Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 2012;12:335-341.
13.
Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ: Long-term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:298-304.
14.
D'Arena G, Rossi G, Vannata B, Deaglio S, Mansueto G, D'Auria F, Statuto T, Simeon V, De Martino L, Marandino A, Del Poeta G, De Feo V: Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. Mediterr J Hematol Infect Dis 2012;4:e2012053.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.